Futibatinib (TAS-120)

futibatinib · Taiho Oncology, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Futibatinib (TAS-120), covering 2026-04-09 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors [Phase 2]